The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment

Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society
Bilge DoganLevent Sevincok

Abstract

The risk factors for depressive symptoms in patients with Parkinson's disease (PD) under dopaminergic drug treatment are unclear. In this study, we examined whether some temperament traits are related to the presence of comorbid depression in PD patients, independent of the characteristics of illness and drug treatment. The participants in this study were 74 patients with idiopathic PD who were already treated with stable doses of levodopa or dopamine agonists. Depressive (n = 20) and non-depressive (n = 52) PD patients were assessed by means of the Unified Parkinson's Disease Rating Scale, Beck Depression Inventory, and Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire. The doses of levodopa and dopamine agonists were converted into levodopa equivalent daily dose. The duration of treatment in the depressive group was significantly longer than in the non-depressive group (P = 0.03). The depressive patients had significantly higher scores on the Unified Parkinson's Disease Rating Scale than the non-depressive patients. Depressive (P < 0.0001), cyclothymic (P < 0.0001), anxious (P < 0.0001), and irritable (P = 0.02) temperament scores were significantly higher in depressive than in non-depressive pat...Continue Reading

References

Apr 1, 1992·The American Journal of Psychiatry·J L Cummings
Nov 1, 1990·Journal of Abnormal Psychology·D N Klein
Jan 1, 1990·The Journal of Nervous and Mental Disease·S E StarksteinR G Robinson
Apr 1, 1986·Brain : a Journal of Neurology·A E TaylorF T Kenny
Mar 1, 1993·Neurology·M A MenzaN E Forman
Jan 1, 1996·Journal of Neural Transmission·W KuhnH Przuntek
Apr 11, 1997·European Journal of Pharmacology·J MajK Kołodziejczyk
Mar 30, 2000·European Archives of Psychiatry and Clinical Neuroscience·J RichterG Richter
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A M KuopioU K Rinne
May 17, 2000·Depression and Anxiety·M H CorriganD L Evans
Mar 3, 2001·Acta Neurologica Scandinavica·H JacobsP Vieregge
Apr 11, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J S LouJ Nutt
May 2, 2001·Parkinsonism & Related Disorders·P M. CarveyZ D. Ling
Jul 13, 2001·The Journal of Neuropsychiatry and Clinical Neurosciences·J R SlaughterM P Martens
Nov 1, 2001·Proceedings of the National Academy of Sciences of the United States of America·V KaasinenJ O Rinne
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Apr 17, 2004·Journal of the American Geriatrics Society·Daniel WeintraubMatthew B Stern
Jun 18, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·R Tomer, J Aharon-Peretz
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine GrossetDonald Grosset
Nov 24, 2004·Journal of Affective Disorders·Marko ElovainioLiisa Keltikangas-Järvinen
Jan 29, 2005·Journal of Neurology·Matthias R LemkeJens Volkmann
Feb 18, 2005·Brain : a Journal of Neurology·Philippe RemyDavid Brooks
Mar 23, 2005·Journal of Affective Disorders·Hagop S Akiskal, Kareen K Akiskal
Mar 23, 2005·Journal of Affective Disorders·Simavi VahipHagop S Akiskal
Mar 23, 2005·Journal of Affective Disorders·Lynn EvansJohn R Kelsoe
Sep 10, 2005·Clinical Neurology and Neurosurgery·Spiridon PapapetropoulosNicoletta P Lekka
Oct 8, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Laura MarshUNKNOWN NINDS/NIMH Work Group on Depression and Parkinson's Disease
Dec 15, 2005·Journal of Abnormal Psychology·Lee Anna Clark
Dec 22, 2005·Acta Neurologica Scandinavica·A Lieberman
Jun 15, 2007·International Journal of Geriatric Psychiatry·Patrick McNamaraErica Harris
Nov 8, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer S A M ReijndersAlbert F G Leentjens
Dec 13, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Sergio E StarksteinRobert G Robinson
Apr 11, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M R Lemke
Jan 15, 2009·Scandinavian Journal of Public Health·Roberto NuevoJosé Luis Ayuso-Mateos
Feb 23, 2010·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Barbara Jasinska-MygaRyan J Uitti
Jul 31, 2010·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Elie G KaramHagop S Akiskal
Dec 21, 2010·Annual Review of Clinical Psychology·Daniel N KleinSara J Bufferd
Jan 26, 2011·Development and Psychopathology·Bruce J EllisMarinus H van Ijzendoorn
Jan 26, 2011·Journal of Affective Disorders·Olli Kampman, Outi Poutanen
Nov 16, 2011·Journal of Neurology·Michele Poletti, Ubaldo Bonuccelli
Jan 3, 2012·Comprehensive Psychiatry·Armando PiccinniLiliana Dell'Osso

❮ Previous
Next ❯

Citations

Nov 2, 2019·The Journal of Sports Medicine and Physical Fitness·Mingjin ZhuYaqun Wang
Aug 18, 2020·Expert Opinion on Pharmacotherapy·Silvia Cerri, Fabio Blandini
Sep 3, 2020·Women & Health·Ahmet SairLevent Sevincok
Oct 22, 2020·International Journal of Psychiatry in Clinical Practice·Sevtap Badil Güloğlu, Serhat Tunç
Mar 28, 2020·Current Stem Cell Research & Therapy·Weitong CuiTianxu Zhang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.